ACHN Achillion Pharmaceuticals Inc.

2.5
+0.03  (+1%)
Previous Close 2.47
Open 2.49
Price To Book 1.24
Market Cap 346540425
Shares 138,616,170
Volume 1,447,214
Short Ratio
Av. Daily Volume 2,789,787

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178
Hepatitis C (HCV)
Phase 2 dosing ongoing in extension trial.
ACH-4471
Paroxysmal nocturnal hemoglobinuria (PNH)
Janssen noted September 11, 2017 that no further development planned.
JNJ-4178 - OMEGA-1
Hepatitis C (HCV)
End of Phase 2 meeting 4Q 2019.
ACH-4471
C3 glomerulopathy (C3G)
Phase 1 multiple ascending dose trial initiation announced January 31, 2019. To be completed 3Q 2019.
ACH-5228
Healthy volunteers

Latest News

  1. Why a Connecticut pharma firm moved its C-suite to Blue Bell
  2. Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
  3. Achillion to Present at the SVB Leerink 8th Annual Global Healthcare Conference
  4. Research Report Identifies The Goodyear Tire & Rubber, Prudential Financial, PennyMac Mortgage Investment Trust, Achillion Pharmaceuticals, American Software, and Lantheus with Renewed Outlook — Fundamental Analysis, Calculating Forward Movement
  5. Achillion Appoints Brian Di Donato as Chief Financial Officer
  6. Alexion's (ALXN) Earnings Beat Estimates in Q4, Shares Up
  7. Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
  8. Alexion's Ultomiris Meets Primary Endpoint in aHUS Study
  9. Here's Why These Small-Cap Pharma Stocks Lost as Much as 45% in December
  10. Top Picks 2019- Achillian Pharmaceuticals ACHN
  11. The Daily Biotech Pulse: Aevi's ADHD Drug Flunks Mid-Stage Trial, Bristol-Myers To Buy Celgene, Teva Settles With Amgen
  12. Achillion Announces Nicole Vitullo Elected to Chair the Board of Directors
  13. 4 Healthcare Stocks That Are Raising Eyebrows
  14. Why Achillion Pharmaceuticals Plunged for a 4th Consecutive Day
  15. Why Achillion Pharmaceuticals Sank Again Today
  16. Achillion Reports Positive Interim Data on Factor D Inhibitors
  17. Why Rent-A-Center, Achillion Pharmaceuticals, and BP Prudhoe Bay Slumped Today
  18. Why Achillion Pharmaceuticals Is Cratering Again Today
  19. The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan
  20. Today's Research Reports on Trending Tickers: Achillion Pharmaceuticals and Synergy Pharmaceuticals